A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic XXXX .

@entity1 @entity137 @entity0 @entity101 @entity7 @entity5 @entity3
@entity7 promotes angiogenesis, an important mediator of growth and @entity3 in @entity1 @entity0 . Bevacizumab, a monoclonal antibody to @entity7 , is under investigation as an anti-angiogenic agent. This phase I/II trial evaluated the safety and efficacy of bevacizumab in @entity1 with previously treated metastatic @entity0 . Seventy-five @entity1 were treated with escalating doses of bevacizumab ranging from 3 mg/kg to 20 mg/kg administered intravenously every other week. @entity5 response was assessed before the sixth (70 days) and 12th (154 days) doses. Safety was evaluated during every cycle. Eighteen @entity1 were treated at 3 mg/kg, 41 at 10 mg/kg, and 16 at 20 mg/kg. Four @entity1 discontinued study treatment because of an adverse event. @entity101 was reported as an adverse event in 17 @entity1 (22%). The overall response rate was 9.3% (confirmed response rate, 6.7%). The median duration of confirmed response was 5.5 months (range, 2.3 to 13.7 months). At the final @entity5 assessment on day 154, 12 of 75 @entity1 (16%) had stable disease or an ongoing response. The optimal dose of bevacizumab in this trial was 10 mg/kg every other week and @entity137 was acceptable. These data support the initiation of trials in metastatic @entity0 combining bevacizumab with chemotherapy.
